Document:

EX-10.2

 Exhibit 10.2 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 NantHealth License Agreement 

This NantHealth License Agreement (this “Agreement”) with an effective date of June 19, 2015 (the “Effective
Date”) is by and between NantHealth, LLC, a Delaware limited liability company (“NantHealth”), on behalf of itself and its Subsidiaries, including eviti, Inc. (“eviti”), and NantOmics, LLC, a Delaware limited
liability company (“Licensee”). The NantHealth and Licensee are sometimes referred to herein as a “Party” and collectively as the “Parties.” 

WHEREAS, the NantHealth and Licensee are parties to that certain NantOmics Exclusive Reseller Agreement (the “Reseller
Agreement”), dated concurrently with the Effective Date, pursuant to which Licensee grants to the NantHealth an exclusive right to resell certain genomic services made available by Licensee; 

WHEREAS, NantHealth has developed, owns and supports certain proprietary software and hardware solutions for use in connection with
patient care, and offers certain content and services to its licensees customers; 
 WHEREAS, as partial consideration for the rights
granted to NantHealth pursuant to the Reseller Agreement, Licensee desires to license from NantHealth certain rights to NantHealth’s products, services and associated content, and NantHealth desires to grant such rights to Licensee; 

WHEREAS, as further partial consideration for the rights granted to NantHealth pursuant to the Reseller Agreement, Licensee desires to
license from NantHealth certain rights to the NantHealth Data (as defined below), and NantHealth desires to grant such rights to Licensee; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties,
intending to be legally bound, agree as follows: 
 1. Definitions. Capitalized terms that are used but not otherwise defined in this
Agreement shall have the meanings set forth below: 
 “Affiliate” means, with respect to a Party, any entity that, at a
given time, directly or indirectly Controls, is Controlled by or is under common Control with, such party. For purposes of this Agreement, (i) NantHealth and its Subsidiaries shall not be deemed to be Affiliates of Licensee and
(ii) Licensee and its Affiliates shall not be deemed to be Affiliates of NantHealth. 
 “BAA” means that certain
Bilateral Business Associate Agreement executed by the Parties. 
 “Confidential Information” means non-public information
of a Disclosing Party or its Affiliates, including (a) any trade secrets and any information relating to the Disclosing Party’s current and planned products and services, technology, source code, techniques, know-how, research,
engineering, designs, finances, accounts, procurement requirements, manufacturing, customer lists, business forecasts, and marketing; (b) any information disclosed in writing that is clearly marked “confidential” or with a similar
proprietary notice at the time of disclosure; (c) any information disclosed verbally that is identified as “confidential” or similarly at the time of disclosure, or which, by its nature, a reasonable person would consider
confidential; (d) the terms and conditions of this Agreement; (e) NantHealth Data; (f) NantOmics Data; and (g) the Content. 

“Content” means the information and/or content available in or on, or accessed or downloaded through or from, the NantHealth
Solutions, including without limitation content relating to cancer treatment (such as clinical trial and treatment information) and rare disease data (including rare disease data obtained by NantHealth in connection with its license of the
“Health Heritage” software). For the avoidance of doubt, Content does not include individually identifiable patient data. 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 1 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 “Control” means the direct or indirect power to direct or cause the
direction of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise. 

“Customer” means any entity that has entered into an agreement with Licensee or its Affiliates to access, use or receive
products, services or other solutions from Licensee or its Affiliates, whether on a commercial or a non-commercial basis. 

“Developer Tools” means all application programming interfaces (“APIs”), software development kits
(“SDKs”), routines, data structures, object classes, variables, protocols, software code and other similar information and materials made available by NantHealth or any of its Subsidiaries to any developers, integrators or other partners,
now and in the future, which can be utilized for integrating, accessing or otherwise interfacing with the NantHealth Solutions and the Content. 

“Eviti Products” means (a) eviti|Advisor; (b) eviti|Connect; (c) all ancillary or associated products, or
improvements or successor products to either (a) or (b) that may be developed by the NantHealth or its Subsidiaries; and (d) all upgrades and updates to (a), (b) or (c). 

“Field” means all uses relating to the following: (i) the discovery, development, evaluation, trial, analysis or
regulatory approval of any pharmaceutical or therapeutic product or treatment, or any companion diagnostic, biomarker, neoantigen or neoepitope; (ii) access by individual consumers, including without limitation patients, for personal or
non-commercial use; and (iii) research, educational, and other non-commercial purposes. 
 “Intellectual Property
Rights” means all present and future patent rights (including but not limited to rights in patent applications or disclosures and rights of priority), copyright (including but not limited to rights in audiovisual works and moral rights),
trade secret rights, trademark rights, and any other intellectual property rights recognized by the law of any applicable jurisdiction. 

“Law” means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree,
or other requirement or rule of any federal, state, local, or foreign government or political subdivision thereof, or any arbitrator, court, or tribunal of competent jurisdiction. 

“Licensee Data” means [***]. 

“Loss” means all losses, damages, liabilities, deficiencies, judgments, settlements, interest, awards, penalties, fines,
costs or expenses of whatever kind, including reasonable attorneys’ fees, the costs of enforcing any right to indemnification hereunder, and the cost of pursuing any insurance providers. 

“NantHealth Data” means [***]. 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 2 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 “NantHealth Trademarks” means the trademarks used by NantHealth and/or its
Subsidiaries in connection with the marketing, sale and branding of its products and services, including without limitation the NantHealth Solutions. 

“NantHealth Solutions” means (i) the eviti Products; (ii) the “Health Heritage” software if, as and when
licensed to NantHealth or any of its Subsidiaries; and (iii) all current and future software and hardware products and services of NantHealth and/or its Subsidiaries (or for which NantHealth or any of its Subsidiaries has the right to license)
with applications or functionality that contemplate direct use by patients or other individual end-users, whether or not such solution is offered on a hosted or non-hosted basis; and (iii) Content. 

“Representatives” means, with respect to a Party or its Affiliates, each of their respective employees, officers, directors,
partners, shareholders, agents, attorneys, and third-party advisors. 
 “Subsidiary” means, with respect to a person, any
other person that is directly or indirectly, through one or more intermediaries, Controlled by such person. 
  

	2.	Licenses and Intellectual Property Ownership. 

 2.1 License Grant.
NantHealth, on behalf of itself and its Subsidiaries, hereby grants to Licensee and its Affiliates a worldwide, non-exclusive, perpetual, sublicensable (solely in order to sublicense to Customers), fully paid-up, right and license, solely in the
Field, to: 
 a. market, distribute, resell, reproduce, transmit, access, make available, prepare derivative works of, modify and otherwise
use the NantHealth Solutions, including without limitation on a white label basis or as made available by NantHealth or its Subsidiaries on a hosted basis; 

b. reproduce, distribute, transmit, prepare derivative works of and modify (to combine with similar materials for related products and
solutions) and otherwise use customer/end user documentation and specifications relating to the NantHealth Solutions; and 
 c. access,
integrate, prepare derivative works of, modify and otherwise use the Developer Tools for the purpose of making the NantHealth Solutions available for use by Licensee, its Affiliates and its Customers (including as an embedded function/service within
Licensee’s or its Affiliates’ products or solutions or through an iframe or similar display module within such product or solution). 

2.2 Licensee Improvements. NantHealth acknowledge and agrees that Licensee and its Affiliates reserve and retain their entire right,
title and interest (including Intellectual Property Rights) in and to any improvements, derivatives works or other modifications to any NantHealth Solutions or Developer Tools developed by or for Licensee or its Affiliates (collectively,
“Licensee Improvements”). However, Licensee, on behalf of itself and its Affiliates, hereby grants to NantHealth and its Subsidiaries a worldwide, non-exclusive, perpetual, sublicensable, fully paid-up, right and license, solely
outside the Field, to reproduce, transmit, access, make available, prepare derivative works of, modify and otherwise use the Licensee Improvements as part of the NantHealth Solutions. 

2.3 Reservation of Rights. Subject to Section 2.2 and the express rights granted by the NantHealth in this Agreement, NantHealth
and its licensors reserve and retain their entire right, title and interest (including Intellectual Property Rights) in and to the NantHealth Solutions, the Developer Tools and the NantHealth Trademarks. Licensee shall not, and shall ensure that its
Affiliates do not, take any action inconsistent with NantHealth’s or its licensors’ ownership and interests set forth in this Section 2, 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 3 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
or assist any person in doing the same. In no event will any transaction contemplated by this Agreement be construed as a sale or assignment of NantHealth’s Intellectual Property Rights.
Furthermore and for the avoidance of doubt, NantHealth expressly reserves, and neither Licensee nor its Affiliates may exercise, any license rights granted herein outside of the Field. 

2.4 Restrictions. Licensee shall not, and shall be responsible to ensure that its Affiliates do not: (a) use, distribute, market,
display, transfer, sublicense, prepare derivative work(s) of or modify or otherwise make available any NantHealth Solutions except as expressly authorized in this Agreement; (b) use or present Content in a manner that is out of context or
presented in a misleading or discriminatory manner; (c) disrupt, disable, place unreasonable burdens or excessive loads on or interfere with the normal operation of the NantHealth Solutions (or their computer systems, servers or networks) as
hosted and made available by NantHealth and its Subsidiaries; or (d) remove, obscure, or alter any notice of NantHealth’s or its licensors’ Intellectual Property Rights present on or in the NantHealth Solutions that are hosted by
NantHealth or its Subsidiaries or any Content, including but not limited to copyright, trademark and/or patent notices. 
 2.5 Trademark
License and Sublicense. 
 a. Subject to the terms and conditions of this Agreement, NantHealth hereby grants to Licensee and its
Affiliates a non-exclusive, perpetual, fully paid-up, right and license to use the NantHealth Trademarks in connection with the marketing, branding, sale, use and sublicensing of the NantHealth Solutions in the Field. 

b. The use of the NantHealth Trademarks must be in accordance with the NantHealth’s trademark use guidelines and instructions, if any,
furnished from time to time to Licensee and its Affiliates. 
 c. All goodwill in and to the NantHealth Trademarks will inure solely to the
benefit of NantHealth and its licensors. 
 2.6 Rights to Licensee Data. [***]. 

2.7 Rights to NantHealth Data [***]. 

2.8 Continuing Obligations of NantHealth Subsidiaries. Notwithstanding anything in this Agreement to the contrary, each entity that is a
Subsidiary of NantHealth shall continue to be bound by the terms of this Agreement even after such entity ceases to be a Subsidiary of NantHealth with respect to any NantHealth Solutions existing immediately prior to the time such entity ceased to
be a Subsidiary of NantHealth. 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 4 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	3.	Other Obligations of the Parties 

 3.1 Support. As part of the licenses
granted in Article 2 hereof, NantHealth and the applicable Subsidiaries will provide to Licensee and its Affiliates reasonable support, issue resolution, cooperation and assistance necessary for the proper operation and use of the NantHealth
Solutions by Licensee and its Affiliates hereunder. However, Licensee acknowledges and agrees that NantHealth and its Subsidiaries are not obligated to support or maintain NantHealth Solutions after such support and maintenance has been discontinued
for NantHealth and its Subsidiaries customers generally. 
 3.2 Service Levels. The hosted NantHealth Solutions made available to
Licensee and its Affiliates hereunder will operate in accordance with acceptable industry standards. 
 3.3 Delivery. Within a
reasonable period of time following Licensee’s request, NantHealth will deliver or otherwise make available to Licensee copies, [***], of the NantHealth Solutions. 

3.4 Professional Services. Licensee and its Affiliates may retain NantHealth to perform professional services (“Professional
Services”) from time to time as the Parties may agree upon in writing in the form of a statement of work. NantHealth will carry out the Professional Services in a professional manner in accordance with acceptable industry standards. Unless
otherwise mutually agreed and outlined in the applicable statement of work, the Professional Services shall be provided by NantHealth on a time and materials basis at NantHealth’s then applicable rates and subject to such deposit or advance
payment as NantHealth may reasonably require. 
 3.5 Customer Agreements. Licensee’s or its Affiliates’ agreements with
Customers must contain terms and conditions no less protective of NantHealth and its licensors than the applicable terms and conditions relating to Licensee’s and its Affiliate’s own products of a similar nature. 

3.6 Insurance. During the term of this Agreement, at such Party’s expense, each Party will maintain policies of insurance with
insurance companies having a financial strength rating no lower than “A-” and a size category not lower than “XII” as rated by the A.M. Best Company, and in amounts which are reasonable and prudent in light of such Party’s
business, potential liabilities to the other Party hereunder, and other relevant factors, including the following: (i) Commercial General Liability insurance with limits not less than One Million U.S. Dollars ($1,000,000) combined single limit
per occurrence and Two Million U.S. Dollars ($2,000,000) aggregate for products, completed operations, personal injury (including death) and property damage arising out of this Agreement; (ii) Errors and Omissions insurance with limits of at
least Five Million U.S. Dollars ($5,000,000) per occurrence and in the aggregate; and (iii) Workers’ Compensation insurance with applicable statutory limits. The policies must contain no exclusions for sole proprietors, executive officers,
partners or members and must have waivers of subrogation. 
  

	4.	Force Majeure. 

 4.1 Force Majeure. Neither Party will be liable or
responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement, when and to the extent such failure or delay is caused by
(a) acts of God; (b) flood, fire, or explosion; (c) war, terrorism, invasion, riot, or other civil unrest; or (d) embargoes or blockades in effect on or after the Effective Date (each of the foregoing, a “Force Majeure
Event”); 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 5 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 4.2 Obligations. Section 4.1 will only apply to the extent (a) the
Force Majeure Event is outside the reasonable control of the affected Party and is not due to the affected Party’s fault or negligence; (b) the affected Party provides notice of the Force Majeure Event to the other Party, stating the
period of time the occurrence is expected to continue; and (c) the affected Party uses diligent efforts to end the failure or delay and minimize the effects of such Force Majeure Event. 

 

	5.	Confidentiality. 

 5.1 Obligations. From time to time in connection with
this Agreement, either Party (as the “Disclosing Party”) has or may disclose or make available to the other Party or its Affiliates (each, the “Receiving Party”) Confidential Information, whether before or after the
Effective Date. In such cases, and subject to the exceptions and limitations expressly set forth in this Agreement, the Receiving Party will (a) not use the Disclosing Party’s Confidential Information, or permit it to be accessed or used,
for any purpose other than to exercise its rights or perform its obligations under this Agreement; and (b) except as otherwise permitted pursuant to this Agreement, not disclose the Disclosing Party’s Confidential Information to any Person
except to its Representatives who need to know the Confidential Information in order to assist the Receiving Party, or to act on its behalf, in exercising the Receiving Party’s rights or performing the Receiving Party’s obligations under
this Agreement, where such Representatives are themselves bound by nondisclosure agreements or obligations as least as restrictive as those set forth in this Section 5.1. The Receiving Party will be responsible for any breach of, or
non-compliance with, this Section 5.1 by its Representatives. The obligation not to use or disclose a Party’s Confidential Information will remain in effect until one of the exceptions in Section 5.2 applies. 

5.2 Exceptions. The restrictions set forth in Section 5.1 will not apply to Confidential Information that, at the time of
disclosure to or receipt by the Receiving Party or its Representatives: (a) is in the public domain or is or becomes generally available to and known by the public other than resulting from, directly or indirectly, any breach of this
Section 5 by the Receiving Party or its Representatives; (b) is or becomes available to the Receiving Party or any of its Representatives on a non-confidential basis from a third party; provided, that such third party is not
and was not prohibited from disclosing the Confidential Information; or (c) was or is independently developed by the Receiving Party or its Representatives without reference to or use of, in whole or in part, any of the Disclosing Party’s
Confidential Information. 
 5.3 Legally Required Disclosure. Notwithstanding anything in this Section 5 to the contrary,
if a Receiving Party or any of its Representatives is required pursuant to applicable Law or the rules or regulations of a stock exchange or similar self-regulatory authority, to disclose any of the Disclosing Party’s Confidential Information,
then the Receiving Party agrees, to the extent legally permissible and as soon as reasonably practicable, to provide the Disclosing Party with written notice of the event so that the Disclosing Party may, at the Disclosing Party’s expense, seek
a protective order or other remedy. The Receiving Party or its Representative (as applicable) will use its commercially reasonable efforts to consult with the Disclosing Party with respect to any effort by the Disclosing Party to resist or narrow
the scope of such requirement or request, or to seek such protective order or other remedy. If such protective order or other remedy is not obtained, then the Receiving Party or its Representative (as applicable): (a) may, without liability,
disclose that portion of the Disclosing Party’s Confidential Information that it is required to disclose; and (b) will use its commercially reasonable efforts to have confidential treatment accorded to the Confidential Information so
disclosed. Furthermore, Section 5 will not apply to the disclosure of Confidential Information if such disclosure is necessary to establish rights or enforce obligations under this Agreement, but only to the extent that any such
disclosure is necessary. Any information disclosed pursuant to this Section 5.3 will retain its confidential status for all other purposes. 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 6 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 5.4 Effect of Termination. Upon termination of this Agreement, at the Disclosing
Party’s request, the Receiving Party will, and will cause its Representatives (and, if applicable, its Affiliates) to, promptly return or destroy (at the Receiving Party’s option) all Confidential Information received from the Disclosing
Party in tangible form, together with all copies thereof, in such Person’s possession; provided, however, that the Receiving Party may keep one (1) copy of the Disclosing Party’s Confidential Information: (a) to the
extent necessary to exercise its surviving rights and perform its surviving obligations hereunder; (b) to the extent required to be maintained pursuant to applicable law or to satisfy the Receiving Party’s record retention obligations and
(c) in accordance with its corporate security and/or disaster recovery procedures, to the extent such Confidential Information is in electronic form. The Receiving Party will, upon request, promptly certify in writing that it has complied with
the obligations of this Section 5.4. 
 5.5 Protected Health Information. For the avoidance of doubt, the use and
protection of protected health information received by a Party or its Representatives in its capacity as a Business Associate or subcontractor of a Business Associate will be governed by the terms of the BAA. 

 

	6.	Public Announcements. 

 6.1 Publicity. Except as may be required by
applicable Law or the rules or regulations of a stock exchange or similar self-regulatory authority, neither Party will issue or release any public announcement, statement, press release or other publicity relating to this Agreement without the
prior written consent of the other Party. 
 6.2 Use of Marks. Except as expressly authorized by this Agreement, neither Party will
use the other Party’s trademarks, service marks, trade names, logos, domain names or other indicia of source, origin, association or sponsorship, without the prior written consent of the other Party. 

 

	7.	Representations, Warranties and Covenants. 

 7.1 General Representations and
Warranties. Each of the Parties hereto represents to the other that (a) it is duly organized, validly existing and in good standing under the laws of its jurisdiction of formation; (b) it has the power and authority to enter into this
Agreement and the transactions contemplated hereby, the execution, delivery and performance of this Agreement and the transactions contemplated hereby have been duly authorized by all necessary action by such Party, and this Agreement constitutes a
valid and binding obligation of such Party, enforceable against such Party in accordance with its terms; and (c) the execution, delivery and performance of this Agreement, and the performance of the transactions contemplated hereby, by such
Party does not and will not violate any provision of its charter or other organizational documents. 
 7.2 Other Representations,
Warranties and Covenants. 
 a. No Viruses. Each Party will use industry standard measures to scan, detect and delete any computer
software, code or script (including Javascript): (a) designed to disrupt, erase, disable, harm, or otherwise impede in any manner the operation of any software, firmware, hardware, computer system, network, or service; or (b) that
constitutes a virus, time bomb, trap door, executable file virus, Trojan horse, worm, or any other similar harmful, malicious or hidden procedure, routine or mechanism that would damage or corrupt data, storage media, programs, equipment or
communications, or otherwise interfere with operations. 
 b. Compliance With Laws. Each Party will comply with all applicable Laws,
governmental requirements, and industry standards, including those with respect to privacy, data protection, portability, or accountability, applicable to such Party or its personnel with respect to the

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 7 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
NantHealth Solutions and the performance of its obligations and exercise of its rights under this Agreement. Neither Party will, nor permit any third parties to, export, re-export, or release,
directly or indirectly, any Controlled Technology to any country or jurisdiction to which the export, re-export, or release of any Controlled Technology (a) is prohibited by applicable Law or (b) without first completing all required
undertakings (including obtaining any necessary export license or other governmental approval). As used herein, “Controlled Technology” means any software, documentation, technology, or other technical data, or any products that
include or use any of the foregoing, of which the export, re-export, or release to certain jurisdictions or countries is prohibited or requires an export license or other governmental approval under any Law, including the U.S. Export Administration
Act and its associated regulations. 
 7.3 Disclaimer. EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES MADE BY THE PARTIES IN
THIS AGREEMENT AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, NO PARTY HERETO MAKES ANY REPRESENTATIONS OR WARRANTIES. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH PARTY EXPRESSLY DISCLAIMS ANY AND
ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, OR NONINFRINGEMENT. 
  

	8.	Indemnification. 

 8.1 Indemnification. Subject to the provisions of this
Section 8, each Party agrees to defend the other party and its Affiliates and its and their respective officers, directors, employees, representatives, agents and users (the “Indemnified Persons”) from and against any
and all third party claim, action, suit or proceeding (each, a “Claim”) and indemnify and hold the Indemnified Persons harmless from and against any and all Losses incurred or sustained by the Indemnified Persons, to the extent such
Claim and related Loss is a result of any of the following: 
 a. any violation of applicable Law by the indemnifying party; 

b. any gross negligence or willful misconduct in connection with the performance of any covenant or agreement applicable to the indemnifying
Party contained in this Agreement (including the performance of the Services), including any personal injury, death or damage to tangible personal or real property; 

c. taxes assessed or claimed against any of the Indemnified Persons that are obligations of the indemnifying Party in connection with this
Agreement or which result from the breach of this Agreement by the indemnifying Party; and 
 d. in the case of NantHealth, any Claim that
NantHealth’s products, services and trademarks, including without limitation the NantHealth Solutions, the Developer Tools and NantHealth Trademarks or the use, sale or delivery of any of the foregoing in accordance with this Agreement,
infringe, misappropriate, or violate any Intellectual Property Right or other right of a third party (each, an “Infringement Claim”), including damages suffered by the Indemnified Persons’ Customers and end users as a result
thereof for which the Indemnified Persons are liable. 
 8.2 Infringement Remedy. In the event of an Infringement Claim, or if any of
the NantHealth Solutions, the Developer Tools or the NantHealth Trademarks is enjoined or threatened to be enjoined, then NantHealth will, at its sole cost and expense, (a) procure for the Indemnified Persons the right to continue to receive
and use such item to the full extent contemplated by this Agreement; 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 8 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
(b) modify or replace the elements that infringe or are alleged to infringe to make them non-infringing while providing reasonably equivalent services, features and/or functionality (as
applicable); or (c) if neither (a) or (b) are commercially practicable, terminate this Agreement immediately, but solely with respect to the portion of the products or services infringing or alleged to infringe. 

8.3 Exclusions from Indemnification. Notwithstanding Sections 8.1 and 8.2 hereof, NantHealth will have no obligation or
liability with respect to any Claim or action regarding any Claim that results from the following: (a) unauthorized modifications to NantHealth’s products or services by any Indemnified Person; (b) the combination, operation or use of
the NantHealth’s products or services with other products, processes or materials if the NantHealth’s products or services themselves do not infringe; (c) the Indemnified Persons’ continued engagement in infringing or allegedly
infringing activities after receipt of notice from NantHealth of a Claim and after being provided with modifications that would have avoided the alleged infringement; or (d) any marketing, sale or use of NantHealth’s products or services
that is not in compliance with this Agreement. 
 9. Limitation of Liability. EXCEPT WITH RESPECT TO: [***] TO THE MAXIMUM
EXTENT PERMITTED BY LAW, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED, AND UNDER WHATEVER CAUSE OF ACTION
OR THEORY OF LIABILITY (INCLUDING UNDER ANY CONTRACT, NEGLIGENCE OR OTHER TORT THEORY OF LIABILITY), EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, A PARTY’S AGGREGATE
LIABILITY FOR DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL NOT EXCEED THE GREATER OF (I) [***] AND (II) [***]. 
  

	10.	Termination. 

 10.1 Termination for Cause. Either Party may
terminate this Agreement, immediately upon written notice to the other party, if the other Party materially breaches this Agreement and such breach (a) is incapable of cure or (b) being capable of cure, remains uncured sixty (60) days
after the breaching Party receives written notice from the non-breaching Party thereof. 
 10.2 Termination for Insolvency. Either
Party may terminate this Agreement, immediately upon written notice to the other Party, if the other Party: (a) becomes insolvent or admits inability to pay its debts generally as they become due; (b) becomes subject, voluntarily or
involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency Law, which is not fully stayed within seven (7) days or is not dismissed or vacated within forty-five (45) days after filing; (c) is dissolved or
liquidated or takes any action for such purpose; (d) makes a general assignment for the benefit of creditors; or (e) has a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take
charge of or sell any portion of its property or business (and such appointment is not discontinued within sixty (60) days thereafter). 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 9 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 10.3 Termination Right for Infringement. NantHealth may terminate this Agreement in
part in accordance with the terms of Section 8.2. 
 10.4 Effect of Termination. 

a. The termination of this Agreement will not have the effect of terminating any Customer Agreement entered into prior to the effective date of
termination. Each Party will continue to honor commitments made under the terms and conditions of each such Customer Agreement for up to three (3) years after the effective date of termination of this Agreement. 

b. Upon termination of this Agreement, except in connection with the rights and obligations set forth in this Section 10.4,
(i) Licensee shall promptly cease all use of the NantHealth Trademarks and any marketing of the Content to prospective Customers; (ii) if this Agreement is terminated by NantHealth under Section 10.1 or 10.2, then
Licensee and its Affiliates shall promptly discontinue use of the NantHealth Data and delete and otherwise remove or destroy all other copies the NantHealth Data that is in Licensee’s possession or control; and (iv) if this Agreement is
terminated by Licensee under Section 10.1 or 10.2, then NantHealth shall promptly discontinue use of the Licensee Data and delete and otherwise remove or destroy all other copies the Licensee Data that is in the NantHealth’s
possession or control. 
 10.5 Survival. The provisions of Sections 1 (Definitions), Section 2.2 (Licensee
Improvements), Section 2.3 (Reservation of Rights), Section 2.4 (Restrictions), Section 2.6 (Rights to Licensee Data) (except to the extent this Agreement is terminated by Licensee under Section 10.1
or 10.2), Section 2.7 (Rights to NantHealth Data) (except to the extent this Agreement is terminated by NantHealth under Section 10.1 or 10.2), Section 4 (Force Majeure), Section 5
(Confidentiality), Section 7.3 (Disclaimer), Section 8 (Indemnification), Section 9 (Limitation of Liability), Section 10.4 (Effect of Termination), this Section 10.5 (Survival), and
Section 11 (Miscellaneous) will survive and continue after expiration or termination of this Agreement indefinitely. Further, the provisions of Section 7 (Representations, Warranties and Covenants) will survive and continue
after termination of this Agreement for the full duration of any Customer Agreement, but in each case solely with respect to any such continuing Customer Agreement. In addition, the rights and obligations of any Party which, by their nature, extend
beyond the termination of this Agreement will continue in full force and effect notwithstanding the termination of this Agreement. 
  

	11.	Miscellaneous. 

 11.1 Relationship of the Parties. The relationship between
the Parties is that of independent contractors. Nothing contained in this Agreement will be construed as creating any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship between the Parties.
Neither Party will have authority to contract for or bind the other Party in any manner whatsoever, except as expressly set forth in this Agreement. 

11.2 Notices. All notices hereunder will be in writing and addressed to a Party at the address set forth under such Party’s name on
the signature page hereto (or as otherwise specified by a Party in a notice given in accordance with this Section 11.2). Notices sent in accordance with this Section 11.2 will be deemed effectively given: (a) when
received, if delivered by hand (with written confirmation of receipt); (b) when received, if sent by a nationally recognized overnight courier (receipt requested); or (c) on the third
(3rd) day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. 

11.3 Interpretation. For purposes of this Agreement, (a) the words “include,” “includes,” and
“including” will be deemed to be followed by the words “without limitation”; (b) the word “or” is not 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 10 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
exclusive; and (c) the words “herein,” “hereof,” “hereby,” “hereto,” and “hereunder” refer to this Agreement as a whole. Unless the context
otherwise requires, references herein: (i) to Sections refer to the sections of this Agreement; (ii) to an agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified
from time to time to the extent permitted by the provisions thereof; and (iii) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This
Agreement will be construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing an instrument to be drafted. The headings in this Agreement are for reference only and
will not affect the interpretation of this Agreement. 
 11.4 Assignment. Neither Party may assign or otherwise transfer any of its
rights, or delegate or otherwise transfer any of its obligations or performance, under this Agreement, in each case whether voluntarily or involuntarily, without the other Party’s prior written consent, which will not be unreasonably withheld,
conditioned, or delayed; provided, however, that (i) Licensee may assign this Agreement to an Affiliate with the capability to provide and perform the obligations of Licensee, or (b) either Party may assign this Agreement to a third party
that receives all or substantially all of the assets to which this Agreement relates. Any assignment, delegation, or other transfer without such prior written consent will be null and void. This Agreement is binding upon and inures to the benefit of
the Parties and their respective permitted successors and assigns. 
 11.5 Rights of Affiliates; Third Party Beneficiary Status.
[***]. 
 11.6 Amendment and Modification; Waiver. This Agreement may only be amended, modified or supplemented by an agreement in
writing signed by each Party. No waiver by any Party of any of the provisions hereof will be effective unless explicitly set forth in writing and signed by the Party so waiving. Except as otherwise set forth in this Agreement, no failure to
exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement will operate or be construed as a waiver thereof; nor will any single or partial exercise of any right, remedy, power or privilege hereunder preclude
any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 
 11.7 Severability. If any
provision of this Agreement or the application thereof to any Party or circumstances is declared void, illegal, or unenforceable, then the remainder of this Agreement will be valid and enforceable to the extent permitted by applicable Law. 

11.8 Governing Law. This Agreement will be governed by and construed in accordance with the Laws of the State of California applicable
to agreements made and to be performed wholly within that State without regard to its conflicts of laws provisions. 
 11.9 Dispute
Resolution. 
 (a) Informal Resolution. Except as otherwise provided in this Agreement, in the event of any dispute, claim, or
controversy arising under, out of, or in connection with this Agreement (a “Dispute”), including as to the breach, performance, or interpretation of this Agreement or the rights, duties or liabilities of either Party hereunder, the
Parties will first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. If such Dispute is not resolved on an 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 11 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
informal basis within thirty (30) days, each Party may, at its sole discretion, seek resolution of such matter in accordance with Section 11.9(b) and exercise its rights
according to any other applicable sections of this Agreement. 
 (b) Arbitration. Except as otherwise expressly provided in this
Section, if the Parties do not reach a mutually acceptable resolution pursuant to Section 11.9(a) as to a Dispute, the Dispute shall be referred for resolution by final, binding arbitration in accordance with the provisions of this
Section. The arbitration shall be conducted by the American Arbitration Association (or any successor entity thereto) (“AAA”) under its rules of commercial arbitration then in effect, except as modified in this Agreement. The
arbitration shall be conducted in the English language, by a single arbitrator knowledgeable in the subject matter at issue in the Dispute and acceptable to both Parties; provided, however, that the Parties may by mutual agreement elect to have the
arbitration conducted by a panel of three arbitrators (such single arbitrator or panel, the “Arbitrator”). The Arbitrator shall, if appropriate, engage an independent expert with experience in the subject matter of the Dispute to
advise the Arbitrator. 
 (i) With respect to any Dispute referred to arbitration pursuant to this Section 11.9,
the Parties and the Arbitrator shall use all reasonable efforts to complete any such arbitration within three (3) months from the issuance of notice of a referral of any such Dispute to arbitration. The Arbitrator shall determine what discovery
will be permitted, consistent with the goal of limiting the cost and time which the Parties must expend for discovery; provided that the Arbitrator shall permit such discovery as he or she deems necessary to permit an equitable resolution of the
Dispute. 
 (ii) The decision of the Arbitrator shall be the sole, exclusive, and binding remedy between them regarding the
Dispute presented to the Arbitrator. Any decision of the Arbitrator may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. The arbitration proceedings and the decision of the
Arbitrator shall not be made public without the joint consent of the Parties, and each Party shall maintain the confidentiality of such proceedings and decision. 

(iii) Unless otherwise agreed by the Parties, the arbitration proceedings shall be conducted in Los Angeles, California. The
Parties shall share equally the cost of the arbitration filing and hearing fees, the cost of the independent expert retained by the Arbitrator, and the cost of the Arbitrator and administrative fees of AAA. Each Party shall bear its own costs and
attorneys’ and witnesses’ fees and associated costs and expenses. 
 (c) Temporary Relief. Pending the selection of the
Arbitrator or pending the Arbitrator’s determination of the merits of any Dispute, either Party may seek appropriate interim or provisional relief from any court of competent jurisdiction as necessary to protect the rights or property of that
Party. 
 11.10 Waiver of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON
OR ARISING OUT OF THIS AGREEMENT OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING
CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. 
 11.11 Equitable Relief.
Notwithstanding anything else in this Agreement to the contrary, each Party acknowledges that a breach by a Party of this Agreement may cause the non-breaching Party immediate and irreparable harm, for which an award of damages may not be adequate
compensation and 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 12 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
agrees that, in the event of such breach or threatened breach, the non-breaching Party will be entitled to seek equitable relief, including in the form of orders for preliminary or permanent
injunction, specific performance, interim or conservatory relief, and any other relief that may be available for any court, and the Parties hereby waive any requirement for the securing or posting of any bond in connection with such relief. Such
remedies will not be deemed to be exclusive but will be in addition to all other remedies available under this Agreement, at law or in equity, subject to any express exclusions or limitations in this Agreement to the contrary. 

11.12 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together
will constitute one and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including .pdf or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission method, and any counterpart
so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 11.13 Entire
Agreement. This Agreement, together with the BAA, constitutes the sole and entire agreement between the Parties solely with respect to the subject matter hereof, and supersedes all prior and contemporaneous understandings and agreements, both
written and oral, with respect to such subject matter. There are no agreements, representations, warranties, covenants or undertakings with respect to the subject matter hereof other than those expressly set forth herein. 

[Signature Page Follows] 

  

			
	 NantHealth License Agreement

CONFIDENTIAL
	 	 Page 13 of 14

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 IN WITNESS WHEREOF, the parties have executed this Content License Agreement as of the Effective Date. 

 

							
	NantOmics, LLC	  	Nant Health, LLC
				
	By:	 	 /s/ Charles Kim
	  	By:	  	 /s/ Robert Watson

	Name:	 	 Charles Kim
	  	Name:	  	 Robert Watson

	Title:	 	 General Counsel
	  	Title:	  	 President

		
	Address for Notices:	  	Address for Notices:
		
	9920 Jefferson Blvd.	  	9920 Jefferson Blvd.
	Culver City, CA 90232	  	Culver City, CA 90232
	Attention: General Counsel	  	Attention: President

  
 14EX-10.3

 Exhibit 10.3 

EXECUTION COPY 

REGISTRATION RIGHTS AGREEMENT 
 THIS
REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of the 25th day of October, 2012, by and among Nant iD, LLC, a Delaware limited liability company (the “Company”), Verizon Investments LLC, a Delaware limited liability
company (“Verizon”), and NantWorks, LLC, a Delaware limited liability Company (“NantWorks” and, together with Verizon, the “Investors”). 

RECITALS 
 WHEREAS, the Investors are parties to that certain
Amended and Restated Limited Liability Company Agreement of the Company, dated as of October 19, 2012 (the “LLC Agreement”); 
 WHEREAS,
pursuant to Section 6.13 of the LLC Agreement, the parties have agreed to enter into this Agreement in order to set forth certain rights and obligations with respect to the registration of the equity securities of the Company; 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, the parties agree as follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under
common control with such Person, including without limitation any general partner, managing member, officer or director of such Person. 
 1.2
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other 

 
federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement
of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act,
the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.3 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.4 “Excluded Registration” means: (i) a registration relating-to the sale of securities to employees of the Company or a subsidiary pursuant
to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included
in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only equity securities being registered are equity securities issuable upon conversion of debt securities that are also being
registered. 
 1.5 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under
the Securities Act subsequently adopted by the SEC. 
 1.6 “Form S-3” means such form under the Securities Act as in effect on the date hereof or
any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

 1.7 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.8 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, ‘ spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.9 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement. 

1.10 “IPO” means the Company’s first underwritten public offering of its equity securities under the Securities Act. 

1.11 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity. 

1.12 “Registrable Securities” means all Units or any equity security issuable upon conversion of or exchange for Units; excluding in all cases,
however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any equity securities for which
registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 
 1.13 “Registrable Securities then outstanding” means the
number of equity securities determined by adding the number of outstanding Units that are Registrable Securities and the number of Units issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are
Registrable Securities. 
 1.14 “SEC” means the Securities and Exchange Commission. 

1.15 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

 1.16 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities. Act. 

1.17 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

1.18 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.19 “Units” means the Series A Units and the Series B Units of the Company. 

2. Registration Rights. The Company covenants and agrees as follows:. 

2.1 Demand Registration. 
 (a) If at any time after the earlier
of (i) October 2, 2018 or (ii) six (6) months after the effective date of the registration statement for the IPO, the Company receives a request from Holders of fifty percent (50%) of the Registrable Securities consisting of
Series B Units (or any security issuable upon conversion of, or in exchange for, Series B Units) then outstanding that the Company file a Form S-1 registration statement with respect to the Registrable Securities then outstanding, provided that the
anticipated aggregate offering price, net of Selling Expenses, would exceed $30 million, then the Company shall (i) within twenty (20) days after the date such request is given, give notice thereof (the “Demand Notice”) to all
Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within ninety (90) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the
Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by
each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(d) and Subsection 2.3. 

 (b) If at any time after the effective date of the registration statement for the IPO, the Company receives a
request from Holders of fifty percent (50%) of the Registrable Securities (or any security issuable upon conversion of, or in exchange for the Registrable Securities) then outstanding that the Company file a Form S-1 registration statement with
respect to the Registrable Securities then outstanding, provided that the anticipated aggregate offering price, net of Selling Expenses, would exceed $30 million, then the Company shall (i) within twenty (20) days after the date such
request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within ninety (90) days after the date such request is given by the Initiating Holders, file a Form
S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other
Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(d) and Subsection 2.3. 

(c) If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least five percent
(5%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling
Expenses, of at least $10 million, then the Company shall (i) within twenty (20) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in
any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(d) and Subsection 2.3. 

 (d) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration
pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its equity
holders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;
or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing for a period of not more than ninety
(90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any
securities for its own account or that of any other equity holder during such ninety (90) day period other than an Excluded Registration. 
 (e) The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of,
and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration
statement to become effective; (ii) after the Company has effected one 

 
registration pursuant to Subsection 2.1(a); (iii) if the Initiating Holders propose to dispose of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request
made pursuant to Subsection 2.1(c); or (iv) if the Initiating Holders have initiated a demand registration pursuant to Subsection 2.1(b), during the period commencing on the date such Initiating Holders have given a Demand Notice and ending on
the date that is one hundred eighty (180) days after the effective date of the registration statement filed in respect of such Demand Notice. The Company shall not be obligated to effect, or to take any action to effect, any registration
pursuant to Subsection 2.1(b) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date
of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected one registration
pursuant to Subsection 2.1(b) within the twelve (12) month period immediate preceding the date of such request; or (iii) if the Initiating Holders propose to dispose of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Subsection 2.1(c) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(c) (i) during the period that is thirty (30) days before
the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith
commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(c) within the twelve (12) month period immediately preceding the
date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(e) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders
withdraw their request for such registration, elect not to pay the 

 
registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as
“effected” for purposes of this Subsection 2.1(e). 
 2.2 Company Registration. If the Company proposes to register (including, for this purpose,
a registration effected by the Company for equity holders other than the Holders) any of its equity securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by
it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration
shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an
underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be
reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in
such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the 

 
extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an
underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing underwriter advises the Initiating Holders in writing that marketing factors
require a limitation on the number of equity securities to the underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten, pursuant hereto, and the number of Registrable
Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each
Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other
securities are first entirely excluded from the underwriting. To facilitate the allocation of equity securities in accordance with the foregoing provisions, the Company or the underwriters may round the number of equity securities allocated to any
Holder to the nearest multiple of 100 securities. 
 (b) In connection with any offering involving an underwriting of the Company’s equity securities
pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
equity holders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the

 
Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included
in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such
selling Holders. To facilitate the allocation of equity securities in accordance with the foregoing provisions, the Company or the underwriters may round the number of equity securities allocated to any Holder to the nearest multiple of 100
securities. Notwithstanding the foregoing, in no event shall the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the
offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members,
stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a
single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as
defined in this sentence. 
 (c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise
of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than thirty five percent (35%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually
included. 

 2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep
such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred
twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of equity securities of the Company, from selling any securities included in such registration; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration
statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders, without charge, such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or
blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or
jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

 (e) in the event of any underwritten public offering, enter into and perform its obligations under an
underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all
such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then
listed; 
 (g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for inspection by the
selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial
and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter,
attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective
or a supplement to any prospectus forming a part of such registration statement has been filed; and 

 (j) after such registration statement becomes effective, notify each selling Holder of any request by the
SEC that the Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any
registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under
Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant
to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. The Company shall have no obligation with respect to any registration requested pursuant to Subsection 2.1 if, due to the operation of
this Subsection 2.5, the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the anticipated aggregate offering price required to originally trigger the Company’s
obligation to initiate such registration as specified in Subsection 2.1. 
 2.6 Expenses of Registration. All expenses (other than Selling Expenses)
incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees, fees and disbursements of counsel for the Company; and
the reasonable fees and disbursements (not to exceed $20,000) of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to

 
pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the
Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of
the Registrable Securities agree to forfeit their right to one registration pursuant to Subsection 2.1(a), Subsection 2.1(b) or Subsection 2.1(c), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have
learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information
then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsection 2.1(a), Subsection 2.1(1)) or Subsection 2.1(c). All Selling Expenses relating to Registrable Securities
registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this
Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 2.8
Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 
 (a) To the extent permitted by
law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the
Securities Act) for each such Holder; and each Person, if any, who 

 
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling
Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder,
underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by
law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter
or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling
Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or
defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this 

 Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections
2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder) except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action)
for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement
thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate
counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between
such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any
liability to the indemnified party under this Subsection 2.8, only to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. 

 (d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in
which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate losses,
claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified
party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or
by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to
contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(0 of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this
Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of
willful misconduct or fraud by such Holder. 

 (e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten
public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of
this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those feints are understood and defined in SEC Rule 144, at all times after the effective
date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file with the SEC in a timely manner all
reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement
by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the
Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold 

 
pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC
that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use
such form). 
 2.10 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing
underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of its equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date
specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO or ninety (90) days in the case of any registration other than the IPO), (i) lend; offer; pledge;
sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares or units of the type
of equity security being registered or any securities convertible into or exercisable or exchangeable (directly or indirectly) for such equity securities held immediately before the effective date of the registration statement for such offering or
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to
be settled by delivery of any securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.10 shall not apply (i) in the case of any registration other than the IPO, to Holders of less than five percent (5%) of the
Registrable Securities then outstanding or (ii) to the sale of any equity securities to an underwriter pursuant to an underwriting agreement and shall be applicable to the Holders only if all executive officers and directors are subject to the
same restrictions. The underwriters in connection with such registration are intended third-party 

 
beneficiaries of this Subsection 2.10 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Any discretionary waiver or termination
of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares or units subject to such agreements. 

2.11 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant
to Subsection 2.1 or Subsection 2.2 shall terminate upon the earliest to occur of: 
 (a) the closing of a Liquidity Event (as defined in the LLC
Agreement); 
 (b) a dissolution of the Company pursuant to Article 10 of the LLC Agreement; and 

(c) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s equity securities
without limitation during a three-month period without registration. 
 3. Miscellaneous. 

3.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable
Securities that is (a) an Affiliate of a Holder; or (b) a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Member; provided, however, that (x) the Company
is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a
written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. The 

 
terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein. 
 3.2 Governing Law. This Agreement and al maters arising under or related to this Agreement shall be governed by and construed in accordance with
the substantive laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction. 

3.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may he delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes. 
 3.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be
considered in construing or interpreting Agreement. 
 3.5 Notices. All notices and other communications given or made pursuant to this Agreement shall be
in writing and shall be deemed effectively upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (i) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours,
and if not sent during normal business hours, then on the recipient’s next business day; (i) five (5) days after having ben sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one
(l) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. Al communications shall be sent to the respective parties at
their addresses as set forth on Schedule 

 
A to the LLC Agreement, or principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address
as subsequently modified by written notice given in accordance with this Subsection 3.5. 
 3.6 Amendments and Waivers. Any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the
Registrable Securities then outstanding; provided that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended
or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion. The Company
shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this
Subsection 3.6 shall be binding on al parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be
or construed as a further or continuing waiver of such term, condition, or provision. 
 3.7 Severability. In case any one or more of the provisions
contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or
unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

 3.8 Aggregation of Equity Securities. All shares or units of Registrable Securities held or acquired by
Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

3.9 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the
parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

3.10 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the
jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding
arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in
any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an
inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE
OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE 

 
FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL
OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS
REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

Each party will bear its own costs in respect of any disputes arising under this Agreement. Each of the parties to this Agreement consents to personal
jurisdiction for any equitable action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter jurisdiction. 

3.11 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default
of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach
or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded
to any party, shall be cumulative and not alternative. 
 [Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. 

 

			
	NANT HEALTH, LLC
		
	By:	 	 /s/ Patrick Soon-Shiong

	Name:	 	 Patrick Soon-Shiong

	Title:	 	Chief Executive Officer
	
	VERIZON INVESTMENTS LLC
		
	By:	 	/s/ John W. Diercksen
	Name:	 	John W. Diercksen
	Title:	 	Chairman & CEO
	
	NANTWORKS, LLC
		
	By:	 	 /s/ Charles Kim

	Name:	 	Charles Kim
	Title:	 	General Counsel

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]